|
N
|
1816
|
964
| |
|
Median follow-up, (months, IQR)
|
39.70 (12.89–84.20)
|
44.56 (16.07–82.07)
|
0.410
|
|
Median age (years, range, IQR)
|
36 (18–70, 26–46)
|
38 (18–72, 28–48)
|
< 0.001
|
|
Median time dg to HCT (months, range, IQR)
|
5.7 (1.9–130, 4.6–8)
|
5.6 (2.3–123, 4.5–7.7)
|
0.182
|
|
Median year of HCT (range)
|
2012 (2000–2017)
|
2012 (2000–2017)
|
0.687
|
|
Median donor age (years, range, IQR, missing)
|
34 (4–73, 26–44, 643)
|
35 (10–72, 27–44, 293)
|
0.080
|
|
In vivo TCD
| | |
0.221
|
|
No in vivo TCD
|
1099 (62%)
|
565 (60%)
| |
|
In vivo TCD
|
670 (38%)
|
381 (40%)
| |
|
Data missing
|
47
|
18
| |
|
Remission status at HCT
| | |
0.518
|
|
CR1
|
1580 (87%)
|
847 (88%)
| |
|
CR2
|
236 (13%)
|
117 (12%)
| |
|
ALL subtype
| | |
< 0.001
|
|
B-ALL Ph-negative
|
479 (26%)
|
181 (19%)
| |
|
B-ALL Ph-positive
|
882 (49%)
|
639 (66%)
| |
|
T-ALL
|
455 (25%)
|
144 (15%)
| |
|
Karnofsky score at HCT
| | |
0.203
|
|
< 80%
|
60 (4%)
|
41 (5%)
| |
|
> =80%
|
1639 (96%)
|
861 (95%)
| |
|
Data missing
|
117
|
62
| |
|
Engraftment
| | |
0.459
|
|
Engrafted
|
1732 (98%)
|
925 (99%)
| |
|
Graft failure
|
29 (1.7%)
|
12 (1.3%)
| |
|
Data missing
|
55
|
27
| |
|
Source of stem cells
| | |
0.008
|
|
Bone marrow
|
409 (23%)
|
261 (27%)
| |
|
Blood
|
1407 (78%)
|
703 (73%)
| |
|
Donor type
| | |
0.268
|
|
Matched sibling
|
1041 (57%)
|
531 (55%)
| |
|
Unrelated 10/10 match
|
575 (32%)
|
308 (32%)
| |
|
Unrelated 9/10 match
|
200 (11%)
|
125 (13%)
| |
|
Conditioning
| | |
0.628
|
|
Chemotherapy-based
|
435 (24%)
|
223 (23%)
| |
|
TBI containing
|
1381 (76%)
|
741 (77%)
| |
|
Patient sex
| | |
0.285
|
|
Male
|
1097 (60%)
|
603 (63%)
| |
|
Female
|
717 (40%)
|
361 (37%)
| |
|
Data missing
|
2
|
0
| |
|
Donor sex
| | |
0.267
|
|
Male
|
1107 (62%)
|
606 (64%)
| |
|
Female
|
693 (39%)
|
346 (36%)
| |
|
Data missing
|
16
|
12
| |
|
Donor–recipient sex mismatch
| | |
0.411
|
|
Female to male
|
391 (22%)
|
195 (20%)
| |
|
Other
|
1409 (78%)
|
762 (80%)
| |
|
Data missing
|
16
|
7
| |
|
Patient CMV serology
| | |
0.950
|
|
Negative
|
637 (37%)
|
342 (37%)
| |
|
Positive
|
1090 (63%)
|
582 (63%)
| |
|
Data missing
|
89
|
40
| |
|
Donor CMV serology
| | |
0.690
|
|
Negative
|
790 (46%)
|
414 (45%)
| |
|
Positive
|
927 (54%)
|
502 (55%)
| |
|
Data missing
|
99
|
48
| |
|
CMV donor/recipient
| | |
0.975
|
|
Negative to negative
|
450 (27%)
|
239 (27%)
| |
|
Positive to negative
|
176 (10%)
|
99 (11%)
| |
|
Negative to positive
|
317 (19%)
|
166 (18%)
| |
|
Positive to positive
|
743 (44%)
|
398 (44%)
| |
|
Data missing
|
130
|
62
| |
|
HCT-comorbidity index
| | |
0.128
|
|
1 or 2
|
529 (85%)
|
271 (81%)
| |
|
> =3
|
92 (15%)
|
62 (19%)
| |
|
Data missing
|
1195
|
631
| |
|
GVHD prevention
| | |
0.054
|
|
Cyclosporin
|
124 (7%)
|
60 (6%)
| |
|
Cyclosporin and MTX
|
1247 (70%)
|
702 (74%)
| |
|
Cyclosporin and MMF ± MTX
|
181 (10%)
|
101 (11%)
| |
|
Tacrolimus ± other
|
115 (7%)
|
41 (4%)
| |
|
Other
|
103 (6%)
|
41 (4%)
| |
|
Data missing
|
46
|
19
| |
|
Acute GVHD
| | |
0.139
|
|
Grade 0–I
|
1156 (67%)
|
594 (64%)
| |
|
Grade II–IV
|
564 (33%)
|
329 (36%)
| |
|
Data missing
|
96
|
41
| |
|
Donor lymphocyte infusion
| | |
< 0.001
|
|
None received
|
1681 (93%)
|
846 (88%)
| |
|
Pre-emptive
|
36 (2%)
|
48 (5%)
| |
|
After relapse
|
97 (5%)
|
67 (7%)
| |
|
Data missing
|
2
|
3
| |
